Evgen Pharma CMO highlights “very aggressive” disease on Glioblastoma Awareness Day
–News Direct–
Evgen Pharma PLC (AIM:EVG) chief medical officer Dr Glen Clack takes the opportunity presented by Glioblastoma Awareness Day to speak with Thomas Warner from Proactive about the disease, which is the most common type of malignant brain tumour in adults.
Dr Clack describes glioblastoma as "always very aggressive" and one of the biggest killers of under-40s in the western world, partly because its "vague" symptoms make it difficult to diagnose. He says common symptoms are headaches, loss of appetite, loss of balance, mood swings, nausea, vomiting, personality and behaviour changes, problems with speaking and memory problems.
There is currently no cure for the disease, but treatments are available to manage symptoms and improve patients' quality of life. He says around 250,000 new cases of glioblastoma are diagnosed each year worldwide. Evgen Pharma has been studying the effects of SFX-01 in treating glioblastoma and has seen promising results in preclinical models. The company aims to continue research and raise awareness for glioblastoma to support funding for a cure. Dr Clack encourages viewers to visit braintumourresearch.org for more information.
Contact Details
Proactive UK Ltd
+44 20 7989 0813
View source version on newsdirect.com: https://newsdirect.com/news/evgen-pharma-cmo-highlights-very-aggressive-disease-on-glioblastoma-awareness-day-114635564
Evgen Pharma PLC
COMTEX_437067769/2655/2023-07-20T02:59:23